AC
AMPH icon

AXQ Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

AXQ Capital’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,621
Closed -$246K – 490
2024
Q4 		$246K Buy
+6,621
New +$303K 0.11% 301

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AXQ Capital's AMPH Position: Q1 2025 in Review

AXQ Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2025, closing a stake of 6,621 shares — an estimated $246K sold.

AXQ Capital first reported a position in AMPH in Q4 2024 and held it in 1 quarter. The position peaked at $246K in Q4 2024. 241 funds tracked by Wall St. Rank hold AMPH as of Q1 2025.

  • AXQ Capital reported no remaining Amphastar Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • AXQ Capital sold 6,621 Amphastar Pharmaceuticals shares in Q1 2025, an estimated $246K.
  • AXQ Capital first reported a position in Amphastar Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • AXQ Capital's Amphastar Pharmaceuticals position peaked at $246K in Q4 2024.
  • 241 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2025.

Based on AXQ Capital's 13F filing for Q1 2025, filed 13 May 2025.